GHRP-6 vs IGF-1 LR3
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Growth Hormone Releasing Peptide 6, SKF-110679
GHRP-6 is a synthetic six-amino-acid peptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) that tricks the body into releasing its own growth hormone. It was one of the first growth hormone secretagogues ever made, and the hunt to find out why it worked led scientists straight to the discovery of ghrelin. It has no approval as a drug anywhere and is used only as a research compound.
Also: Long R3 IGF-1, LR3
IGF-1 LR3 is a modified version of insulin-like growth factor 1, engineered to last far longer in the body than the natural hormone. It is popular in physique circles and it is worth being blunt about the evidence: there are effectively no human clinical trials of this specific analog. Everything below the mechanism section is preclinical work, laboratory use, or community reporting.
Key Comparison Insights
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
- GHRP-6 has stronger research evidence (Human Trials) compared to IGF-1 LR3 (Preclinical).
Detailed Comparison
| Attribute | GHRP-6 | IGF-1 LR3 |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | GHRP-6 binds and activates the growth hormone secretagogue receptor type 1a (GHS-R1a), the same receptor later found to be the natural target of the hunger hormone ghrelin. When it switches that receptor on in the pituitary and hypothalamus, the pituitary fires off a pulse of growth hormone. Because GHS-R1a also sits on appetite-driving neurons in the brain (the NPY/AgRP cells of the arcuate nucleus), GHRP-6 is a strong appetite stimulant, more so than the other GHRPs. At higher doses it also nudges up cortisol and prolactin, since the receptor system is not perfectly selective for the GH pathway. | Natural IGF-1 is almost entirely bound up by IGF binding proteins in circulation, which controls how much is active and gives it a half-life measured in minutes. LR3 makes two changes: an arginine substitution at position 3, and a 13-amino-acid extension on the N-terminus. Together these dramatically reduce binding-protein affinity, so far more of the molecule stays free and active, extending the functional half-life to something on the order of a day rather than minutes. Once free, it activates the IGF-1 receptor, driving protein synthesis, satellite cell activation and cell proliferation in muscle. That same lack of binding-protein regulation is the reason for caution: binding proteins are a control mechanism, and removing the control is the point of the drug and also its main risk. |
| Common Dosing | 100-300 mcg 2-3x daily 2-3x daily | 20-50 mcg daily Once daily |
| Administration | Subcutaneous injection, ideally fasted | Subcutaneous injection. Because of the hypoglycemia risk, timing relative to carbohydrate intake is the main practical consideration reported. |
| Typical Duration | 8-12 weeks | Community cycles are typically reported as 4-6 weeks, on the reasoning that receptor downregulation follows longer use |
| Best Time to Take | Before bed or morning (fasted) | With or near a carbohydrate-containing meal |
Possible Side Effects May vary by individual |
|
|
| Research Summary | GHRP-6 has been studied in humans, but mostly as a lab and diagnostic probe rather than as a treatment with large clinical trials behind it. Early work in the 1980s and 1990s showed it reliably triggers growth hormone release, and chasing its mechanism is literally what led Kojima and colleagues to discover ghrelin in 1999, which reframed how we understand hunger and GH control. A 2013 pharmacokinetic study in nine healthy men found oral bioavailability under 1 percent and an elimination half-life around 2.5 hours, which is why it is given by injection. The popular claims about muscle gain, fat loss, and healing in fitness circles are not backed by controlled human outcome trials. It is not approved by the FDA or EMA for any use and remains a research chemical, with appetite stimulation, water retention, and cortisol/prolactin bumps as known effects. | IGF-1 LR3 was developed as a cell culture reagent, and that remains its principal legitimate use: it is sold to laboratories to promote cell growth in bioreactors. There are no published randomized human trials of IGF-1 LR3 for muscle growth, body composition or performance. The animal and in vitro work does show what you would expect, increased protein synthesis and muscle cell proliferation, and there is a genuine human literature on recombinant IGF-1 (mecasermin) for severe IGF-1 deficiency, but mecasermin is a different molecule with different pharmacokinetics and its trial data should not be read across. The two consistent safety themes in the underlying biology are hypoglycemia, because IGF-1 has meaningful cross-reactivity with the insulin receptor, and the theoretical concern that chronically elevated IGF-1 signalling promotes growth of tissue you did not intend to grow, including existing tumors. |
Frequently Asked Questions: GHRP-6 vs IGF-1 LR3
What is the difference between GHRP-6 and IGF-1 LR3?
GHRP-6 is a growth hormone peptide that ghrp-6 is a synthetic six-amino-acid peptide (his-d-trp-ala-trp-d-phe-lys-nh2) that tricks the body into releasing its own growth hormone. it was one of the first growth hormone secretagogues ever made, and the hunt to find out why it worked led scientists straight to the discovery of ghrelin. it has no approval as a drug anywhere and is used only as a research compound. IGF-1 LR3 is a growth hormone peptide that igf-1 lr3 is a modified version of insulin-like growth factor 1, engineered to last far longer in the body than the natural hormone. it is popular in physique circles and it is worth being blunt about the evidence: there are effectively no human clinical trials of this specific analog. everything below the mechanism section is preclinical work, laboratory use, or community reporting. The main differences lie in their mechanisms of action and clinical applications.
Which is better, GHRP-6 or IGF-1 LR3?
Neither is universally "better" - the choice depends on your specific goals. GHRP-6 is typically used for growth hormone purposes, while IGF-1 LR3 is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can GHRP-6 and IGF-1 LR3 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using GHRP-6 and IGF-1 LR3 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.